SwePub
Sök i LIBRIS databas

  Utökad sökning

WFRF:(Toft U)
 

Sökning: WFRF:(Toft U) > (2020-2024) > Asparaginase-Associ...

  • Rank, Cecilie U.Rigshosp, Copenhagen, Denmark;Univ Copenhagen, Copenhagen, Denmark (författare)

Asparaginase-Associated Pancreatitis in Acute Lymphoblastic Leukemia : Results From the NOPHO ALL2008 Treatment of Patients 1-45 Years of Age

  • Artikel/kapitelEngelska2020

Förlag, utgivningsår, omfång ...

  • Alexandria :American Society of Clinical Oncology,2020
  • electronicrdacarrier

Nummerbeteckningar

  • LIBRIS-ID:oai:DiVA.org:umu-168802
  • https://urn.kb.se/resolve?urn=urn:nbn:se:umu:diva-168802URI
  • https://doi.org/10.1200/JCO.19.02208DOI
  • https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-406205URI
  • http://kipublications.ki.se/Default.aspx?queryparsed=id:142782599URI

Kompletterande språkuppgifter

  • Språk:engelska
  • Sammanfattning på:engelska

Ingår i deldatabas

Klassifikation

  • Ämneskategori:ref swepub-contenttype
  • Ämneskategori:art swepub-publicationtype

Anmärkningar

  • PURPOSE: Asparaginase-associated pancreatitis (AAP) is common in patients with acute lymphoblastic leukemia (ALL), but risk differences across age groups both in relation to first-time AAP and after asparaginase re-exposure have not been explored.PATIENTS AND METHODS: We prospectively registered AAP (n = 168) during treatment of 2,448 consecutive ALL patients aged 1.0-45.9 years diagnosed from July 2008 to October 2018 and treated according to the Nordic Society of Pediatric Hematology and Oncology (NOPHO) ALL2008 protocol.RESULTS: Compared with patients aged 1.0-9.9 years, adjusted AAP hazard ratios (HRa) were associated with higher age with almost identical HRa (1.6; 95% CI, 1.1 to 2.3; P = .02) for adolescents (10.0-17.9 years) and adults (18.0-45.9 years). The day 280 cumulative incidences of AAP were 7.0% for children (1.0-9.9 years: 95% CI, 5.4 to 8.6), 10.1% for adolescents (10.0 to 17.9 years: 95% CI, 7.0 to 13.3), and 11.0% for adults (18.0-45.9 years: 95% CI, 7.1 to 14.9; P = .03). Adolescents had increased odds of both acute (odds ratio [OR], 5.2; 95% CI, 2.1 to 13.2; P = .0005) and persisting complications (OR, 6.7; 95% CI, 2.4 to 18.4; P = .0002) compared with children (1.0-9.9 years), whereas adults had increased odds of only persisting complications (OR, 4.1; 95% CI, 1.4 to 11.8; P = .01). Fifteen of 34 asparaginase-rechallenged patients developed a second AAP. Asparaginase was truncated in 17/21 patients with AAP who subsequently developed leukemic relapse, but neither AAP nor the asparaginase truncation was associated with increased risk of relapse.CONCLUSION: Older children and adults had similar AAP risk, whereas morbidity was most pronounced among adolescents. Asparaginase re-exposure should be considered only for patients with an anticipated high risk of leukemic relapse, because multiple studies strongly indicate that reduction of asparaginase treatment intensity increases the risk of relapse.

Ämnesord och genrebeteckningar

Biuppslag (personer, institutioner, konferenser, titlar ...)

  • Wolthers, Benjamin O.Rigshosp, Copenhagen, Denmark (författare)
  • Grell, KathrineRigshosp, Copenhagen, Denmark;Univ Copenhagen, Copenhagen, Denmark (författare)
  • Albertsen, Birgitte K.Aarhus Univ Hosp, Aarhus, Denmark (författare)
  • Frandsen, Thomas L.Rigshosp, Copenhagen, Denmark (författare)
  • Overgaard, Ulrik M.Rigshosp, Copenhagen, Denmark (författare)
  • Toft, NinaHerlev Univ Hosp, Herlev, Denmark (författare)
  • Nielsen, Ove J.Rigshosp, Copenhagen, Denmark (författare)
  • Wehner, Peder S.Odense Univ Hosp, Odense, Denmark (författare)
  • Harila-Saari, Arja H.Uppsala universitet,Barnneurologi/Barnonkologi(Swepub:uu)arjha456 (författare)
  • Heyman, Mats M.Karolinska Univ Hosp, Stockholm, Sweden (författare)
  • Malmros, JohanKarolinska Institutet (författare)
  • Abrahamsson, JonasQueen Silvia Childrens Hosp, Gothenburg, Sweden (författare)
  • Norén-Nyström, UlrikaUmeå universitet,Pediatrik,Umea Univ, Umea, Sweden(Swepub:umu)kagr0007 (författare)
  • Tomaszewska-Toporska, BeataSkane Univ Hosp, Lund, Sweden (författare)
  • Lund, BendikTrondheim Reg & Univ Hosp, Trondheim, Norway (författare)
  • Jarvis, Kirsten B.Oslo Univ Hosp, Oslo, Norway;Univ Oslo, Oslo, Norway (författare)
  • Quist-Paulsen, PetterTrondheim Reg & Univ Hosp, Trondheim, Norway (författare)
  • Vaitkeviciene, Goda E.Vilnius Univ, Hosp Santaros Klin, Vilnius, Lithuania;Vilnius Univ, Vilnius, Lithuania (författare)
  • Griskevicius, LaimonasVilnius Univ, Hosp Santaros Klin, Vilnius, Lithuania;Vilnius Univ, Vilnius, Lithuania (författare)
  • Taskinen, MerviHelsinki Univ Hosp, Helsinki, Finland (författare)
  • Wartiovaara-Kautto, UllaHelsinki Univ Hosp, Helsinki, Finland (författare)
  • Lepik, KristiTallinn Childrens Hosp, Tallinn, Estonia (författare)
  • Punab, MariTartu Univ Hosp, Tartu, Estonia (författare)
  • Jonsson, Olafur G.Reykjavik Univ Hosp, Reykjavik, Iceland (författare)
  • Schmiegelow, KjeldRigshosp, Copenhagen, Denmark;Univ Copenhagen, Copenhagen, Denmark (författare)
  • Rigshosp, Copenhagen, Denmark;Univ Copenhagen, Copenhagen, DenmarkRigshosp, Copenhagen, Denmark (creator_code:org_t)

Sammanhörande titlar

  • Ingår i:Journal of Clinical OncologyAlexandria : American Society of Clinical Oncology38:2, s. 145-1540732-183X1527-7755

Internetlänk

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy